NCT02834884 SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
| NCT ID | NCT02834884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Condition | All Tumor Types |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,975 participants |
| Start Date | 2017-05-03 |
| Primary Completion | 2022-08-29 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Eligibility Criteria
* Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;